www.fdanews.com/articles/199061-novavax-expands-covid-19-vaccine-manufacturing-agreement-with-serum-institute-of-india
Novavax Expands COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India
September 16, 2020
Maryland-based Novavax is aiming to produce 2 billion doses of its COVID-19 vaccine annually by 2021, and it has just expanded a manufacturing agreement with the Serum Institute of India, the world’s largest vaccine developer.
The institute will manufacture the antigen component of NVX-2373, making it one of five manufacturers around the world doing that for Novavax. The institute previously agreed to produce at least 1 billion doses of the Novavax vaccine for low- and middle-income countries.
Novavax President and CEO Stanley C. Erck said the company anticipates starting phase 3 efficacy trials of the vaccine around the world “in the coming weeks.”